William J Turbitt1, Rachael M Orlandella2, Justin T Gibson2, Courtney M Peterson1,3, Lyse A Norian4,3,5. 1. Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, U.S.A. 2. Graduate Biomedical Sciences, University of Alabama at Birmingham, Birmingham, AL, U.S.A. 3. Nutrition Obesity Research Center, University of Alabama at Birmingham, Birmingham, AL, U.S.A. 4. Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, U.S.A. lnorian@uab.edu. 5. O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, U.S.A.
Abstract
BACKGROUND/AIM: Dietary interventions like time-restricted feeding (TRF) show promising anti-cancer properties. We examined whether therapeutic TRF alone or combined with immunotherapy would diminish renal tumor growth in mice of varying body weights. MATERIALS AND METHODS: Young (7 week) chow-fed or older (27 week) high-fat diet (HFD)-fed BALB/c mice were orthotopically injected with renal tumor cells expressing luciferase. After tumor establishment, mice were randomized to ad libitum feeding or TRF +/- anti-CTLA-4. Body composition, tumor viability and growth, and immune responses were quantified. RESULTS: TRF alone reduced renal tumor bioluminescence in older HFD-fed, but not young chow-fed mice. In the latter, TRF mitigated tumor-induced loss of lean- and fat-mass. However, TRF did not alter excised renal tumor weights or intratumoral immune responses and failed to improve anti-CTLA-4 outcomes in any mice. CONCLUSION: Therapeutic TRF exhibits modest anti-cancer properties but fails to improve anti-CTLA-4 immune checkpoint blockade in murine renal cancer. Copyright
BACKGROUND/AIM: Dietary interventions like time-restricted feeding (TRF) show promising anti-cancer properties. We examined whether therapeutic TRF alone or combined with immunotherapy would diminish renal tumor growth in mice of varying body weights. MATERIALS AND METHODS: Young (7 week) chow-fed or older (27 week) high-fat diet (HFD)-fed BALB/c mice were orthotopically injected with renal tumor cells expressing luciferase. After tumor establishment, mice were randomized to ad libitum feeding or TRF +/- anti-CTLA-4. Body composition, tumor viability and growth, and immune responses were quantified. RESULTS:TRF alone reduced renal tumor bioluminescence in older HFD-fed, but not young chow-fed mice. In the latter, TRF mitigated tumor-induced loss of lean- and fat-mass. However, TRF did not alter excised renal tumor weights or intratumoral immune responses and failed to improve anti-CTLA-4 outcomes in any mice. CONCLUSION: Therapeutic TRF exhibits modest anti-cancer properties but fails to improve anti-CTLA-4 immune checkpoint blockade in murinerenal cancer. Copyright
Authors: Stefano Di Biase; Changhan Lee; Sebastian Brandhorst; Brianna Manes; Roberta Buono; Chia-Wei Cheng; Mafalda Cacciottolo; Alejandro Martin-Montalvo; Rafael de Cabo; Min Wei; Todd E Morgan; Valter D Longo Journal: Cancer Cell Date: 2016-07-11 Impact factor: 31.743
Authors: Britnie R James; Kristin G Anderson; Erik L Brincks; Tamara A Kucaba; Lyse A Norian; David Masopust; Thomas S Griffith Journal: Cancer Immunol Immunother Date: 2014-08-21 Impact factor: 6.968
Authors: Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel Journal: Nat Med Date: 2018-04-23 Impact factor: 53.440
Authors: Britnie R James; Ann Tomanek-Chalkley; Eric J Askeland; Tamara Kucaba; Thomas S Griffith; Lyse A Norian Journal: J Immunol Date: 2012-06-27 Impact factor: 5.422
Authors: Vickie E Baracos; Lisa Martin; Murray Korc; Denis C Guttridge; Kenneth C H Fearon Journal: Nat Rev Dis Primers Date: 2018-01-18 Impact factor: 52.329
Authors: William J Turbitt; Shannon K Boi; Justin T Gibson; Rachael M Orlandella; Lyse A Norian Journal: Cancers (Basel) Date: 2021-05-11 Impact factor: 6.639